masthead-publications

Categories

Filter by Topics

ALK Autoimmune Disorder B-cell lines Biology of neoplasia Biomarker Discovery Biomarker Patient Stratification Biomarker Validation Biomarkers Bladder Brain Brain RNA Breast Carcinoma Cell line Cells Cerebral Spinal Fluid Checkpoint Inhibitors Colon Colon cancer Colorectal cancer Cytokines Developmental Immunotherapy DLBCL Drug Response Encephalophy Extracted RNA FFPE Gene Expression Comparisons Gene Expression Profiling Gene Expression Signatures Genetic Polymorphism Histone Deacetylase Inhibitors HTG EdgeSeq HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq System Human serum Immune Checkpoint Inhibitors Immune Response Immune-related Colitis Immuno-Oncology Immunotherapy Inflammatory Signatures Kidney Liposarcoma Liver Lung Lymphoma Melanoma Metastatic Colon Cancer Metastatic Prostate Cancer Methods Comparison Microenvironment miRNA miRNA WTA Molecular Characterization Myocarditis Nash and Fibrosis Natural Killer Cells non-Hodgkin Lymphoma Non-small Cell Lung Cancer NSCLC Oesophageal Adenocarcinoma Overexpression Pancreas Pancreatic Ductal Adenocarcinoma Parkinson's Disease Pathology Plasma Platform Comparison Pralatrexate Predictive Biomarkers Pro-inflammatory cytokines Prognostic Prognostic Biomarkers Programmed cell death protein 1 Programmed death ligand 1 Prostate qNPA qPCR Radioimmunotherapy Renal Cell Carcinoma Responders vs Non-responders Rheumatoid Arthritis Serum Signature Pathway Analysis Skin Small bowel Small cell bladder cancer Sub-typing Survival plots System Validation Technology Comparison Tissue-based biomarkers Transplantation Treatment Outcome Treatment Targets Triple Negative Breast Cancer Tumor Biology Tumor Immunobiology Tumor infiltrating lymphocytes Venetoclas

2020

Sarcomatoid Renal Cell Carcinoma Demonstrates an Immunosuppressive Tumor Microenvironment - Implication for Therapeutic Benefit in the Immunotherapy Era

Hwang, M., et al. Sarcomatoid Renal Cell Carcinoma Demonstrates an Immunosuppressive Tumor Microenvironment - Implication for Therapeutic Benefit in the Immunotherapy Era.  Poster session presented at: United Sstates and Canadian Academy of Pathology (USCAP) 109th Annual Meeting 2020 FEB 29- MAR 5, Los Angeles, CA

Download pptx 4.4MB

Variation in Genetic Polymorphisms and Gene Expression of HLA-E to Predict Outcomes in Metastatic Colorectal Cancer (mCRC) Patients (pts) Treated with First-line FOLFIRI/Cetuximab: Data from the Phase III FIRE-3 Trial.

Naseem, M., et al. Variation in Genetic Polymorphisms and Gene Expression of HLA-E to Predict Outcomes in Metastatic Colorectal Cancer (mCRC) Patients (pts) Treated with First-line FOLFIRI/Cetuximab: Data from the Phase III FIRE-3 Trial. Poster session presented at Gastrointestinal Cancers Symposium. 2020 Jan 25. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 4; abstr 245)

View External Link

CCR5 Δ32 Mutation and Gene Expression to Predict Outcome in Patients (pts) with Metastatic Colorectal Cancer (mCRC): Data From FIRE-3 and MAVERICC Phase III Trials.

Lenz, A., et al. CCR5 Δ32 Mutation and Gene Expression to Predict Outcome in Patients (pts) with Metastatic Colorectal Cancer (mCRC): Data From FIRE-3 and MAVERICC Phase III Trials.  Poster session presented at 2020 Gastrointestinal Cancers Symposium. 2020 Jan 25. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 4; abstr 170)

View External Link

Genetic variants in R-Spondin/RNF43 complex and gene expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.

Battaglin, F., et al. Genetic variants in R-Spondin/RNF43 complex and gene expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial. Poster session  Clin Oncol 38, 2020 (suppl 4; abstr 190) presented at 2020 Gastrointestinal Cancers Symposium; 2020 Jan 25; San Francisco, CA.

View External Link

2019

Translational study associated to a phase II study evaluating the activity of pazopanib in patients (pts) with advanced/metastaticliposarcoma (LPS): A joint Spanish Sarcoma Group (GEIS) and German Int

Valverde, C., et al. Translational  Study Associated to a Phase II Study Evaluating the Activity of Pazopanib in Patients (pts) with Advanced Metastatic Liposarcoma (LPS): A joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) study.  Poster session presented at: American Society of Clinical Oncology (ASCO) Annual meeting,  2019 Jun 3; Chicago, IL.

Download ppt 1.1MB

The Anti-CD25 Antibody-Drug conjugate Camidanlumab Tesirine (ADCT-301) Presents a Strong Preclinical Activity both as Single Agent and in Combination in Lymphoma Cell Lines

Spriano, F. et al. The Anti-CD25 Antibody-Drug Conjugate Camidanlumab Tesirine (ADCT-301) Presents a Strong Preclinical Activity Both as Single Agent and in Combination in Lymphoma Cell Lines. Poster presented at: 15th International Conference on Malignant Lymphoma Palazzo dei Congressi; 2019 Jun 18-22; Lugano, Switzerland.  Hematological Oncology VOL 37, Issue S2. https://doi.org/10.1002/hon.134_2630

Download pdf 2.4MB
View External Link

Translational study associated to a phase II study evaluating the activity of pazopanib in patients (pts) with advanced/metastatic liposarcoma (LPS): a joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) study.

Valverde Morales, C. M., et al. Translational study associated to a phase II study evaluating the activity of pazopanib in patients (pts) with advanced/metastatic liposarcoma (LPS): a joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) study.  American Society of Clinical Oncology (ASCO) Annual Meeting; June 1, 2019, Chicago, IL

View External Link

Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab

Hurwitz, M. E., et al. Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab. Poster session presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 1, 2019, Chicago, IL

View External Link

Gene expression comparison between primary triple-negative breast cancer and matched axillary lymph node metastasis

Srour, M. et al. Gene expression comparison between primary triple-negative breast cancer and matched axillary lymph node metastasis. Poster session presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; 2019 Jun 2, Chicago, IL.

Download pdf 1.2MB
View External Link

Association of an Inflammatory Gene Signature with CD8 Expression by Immunohistochemistry (IHC) in Multiple Tumor Types.

Szabo, P. M., et al. Association of an Inflammatory Gene Signature with CD8 Expression by Immunohistochemistry (IHC) in Multiple Tumor Types. Poster session presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 1, 2019, Chicago, IL.

Download pdf 606KB
View External Link

Page last updated April 06, 2020